TNKASE (tenecteplase) - Roche, Boehringer Ingelheim
Tenecteplase versus standard care for minor ischaemic stroke according to the baseline occlusion status in TEMPO-2 trial. (PubMed, Eur Stroke J) - Sep 15, 2026 - P3 | "There was no difference in outcome between tenecteplase and standard care for patients with mild stroke based on their baseline vessel occlusion status." 
Clinical • Journal • Cardiovascular • CNS Disorders • Hypertension • Ischemic stroke • Vascular Neurology
http://www.ncbi.nlm.nih.gov/pubmed/42734928
 
; Aravind Ganesh; Bruce C V Campbell; Daniel Strbian; Liisa Tomppo; Mark W Parsons; Michael D Hill; Nishita Singh; Shabnam Vatanpour; Shelagh B Coutts; Silja Räty
 
Sep 15, 2026
 
Prev Next